Psychol Health 2004, 19: 749–765.CrossRef 10. Schlich-Bakker KJ, ten Kroode HFJ, Ausems MGEM: A literature review of the psychological impact of genetic testing on breast cancer patients. Patient Educ Couns 2006, 60: 13–20.CrossRef 11. Kelly K, Leventhal H, Marvin M, Toppmeyer D, Much J, Dermody J, Baran J, Schwalb M: Subjective and objective risk of breast cancer in Ashkenazi Jewish individuals at risk for BRCA1/2 mutations.
Genet Test 2004, 8: 139–47.PubMed 12. Kelly KM, Senter L, Leventhal H, Ozakinci G, Porter K: Subjective and objective risk of ovarian cancer in Ashkenazi Jewish women testing for BRCA1/2 mutations. Patient Educ Couns 2008, 70: 135–142.CrossRefPubMed 13. D’Agincourt-Canning L: The effect of experimental knowledge on construction of risk perception in hereditary breast/ovarian cancer. J Genet https://www.selleckchem.com/products/DAPT-GSI-IX.html Couns 2005, 14: 55–69.CrossRefPubMed 14. Katapodi MC, Lee KA, Facione NC, Dodd MJ: buy BKM120 Predictors of perceived breast cancer risk and relation between perceived risk and breast cancer screening: a meta-analytic review. Prev Med 2004, 39: 388–402.CrossRef 15. Daly MB, Lerman C, Ross E, Schwartz MD, Sands CB, Masny ATM signaling pathway A: Gail Model breast cancer risk components are poor predictors of risk perception and screening behaviour. Breast Cancer Res Treat 1996, 41: 59–70.CrossRefPubMed 16.
Walter FM, Emery J, Braithwaite D, Marteau TM: Lay understanding of familial risk of common chronic disease: A systematic review and synthesis of qualitative research. Ann Fam Med 2004, 2: 583–594.CrossRefPubMed 17. Quillin JM, McClish DK, Jones RM, Burruss K, Bodurtha JN: Spiritual coping, family history and perceived risk for breast cancer-can we make sense of it? J Genet Couns 2006, 15: 449–460.CrossRefPubMed 18. Gil F, Mendez
I, Sirgo A, Llort G, Blanco I, Cortes-Funes L: Perception of breast cancer risk and surveillance behaviours of women with family history of breast cancer: a brief report on a Spanish cohort. Psychooncology 2003, 12: 821–827.CrossRefPubMed Chlormezanone 19. Caruso A, Vigna C, Maggi G, Sega FM, Cognetti F, Savarese A: The withdrawal from oncogenetic counseling and testing for hereditary and familial breast and ovarian cancer. A descriptive study of an Italian sample. J Exp Clin Cancer Res 2008, 27: 75–82.CrossRefPubMed 20. Berry DA, Iversen ES Jr, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, Rubinstein WS, Hughes KS, Parmigiani G: BRCAPRO validation, sensitivity of genetic testing of BRCA1/2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 2002, 20: 2701–2712.CrossRefPubMed 21. Parmigiani G, Berry DA, Aguilar O: Modelling risk of breast cancer and decisions about genetic testing. Am J Hum Genet 1998, 62: 145–148.CrossRefPubMed 22.
- Pazopanib in BRCA1/2 genes have been detected in reliable tumors
- We have screened for BRCA1 and BRCA2 mutations 110 women diagnose
- Comparison of PR and HER2 status involving ER BRCA1 breast cancer
- Cancer Genet Cytogenet 2003, 140: 145–152 CrossRefPubMed 10 Cher
- CrossRef 17 Quaglino P, Ribero S, Osella-Abate S, Macrì L, Grass